Bio-Rad Releases Labeled Antibodies for Fluorescent Multiplex Detection of Proteins in Western Blots

Date: 
4/19/17

StarBright Blue 700 Secondary Antibodies Offer Improved Sensitivity among Fluorescent Dye Labeled Secondary Antibodies

Bio-Rad's fluorescent western blotting workflow

The StarBright Blue 700 Secondary Antibodies and hFAB Rhodamine Anti-Housekeeping Protein Primary Antibodies are part of Bio-Rad’s fluorescent western blotting workflow for obtaining reliable, high-quality results.

HERCULES, Calif. — April 19, 2017 — Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of StarBright™ Blue 700, fluorescent dye labeled secondary antibodies for use in multiplex western blotting with a two- to fourfold lower limit of detection than IR800 labeled antibodies, the current industry standard. The company is also launching hFAB™ Rhodamine Anti-Housekeeping Protein Primary Antibodies for one-step detection of housekeeping proteins using western blots.

Detecting and quantifying multiple proteins simultaneously using western blotting can be challenging. Researchers are faced with performing either several time-consuming and error-prone chemiluminescent western blots or one fluorescent blot, which involves waiting up to 10 minutes to detect a signal that might be obscured by high background noise due to nonspecific binding.

To address those workflow challenges, Bio-Rad created StarBright Blue 700, a line of secondary antibodies that offer highly sensitive fluorescent detection, short exposure times, and easy multiplexing for western blotting.

The StarBright Blue 700 Secondary Antibodies are labeled with a fluorescent dye that is exceptionally bright thanks to the multiple donor-acceptor pairs present in each polymer molecule that allow it to efficiently accept and emit light. The 700 nm (near infrared) emission  of StarBright Antibodies results in minimal background signal, and the conjugation to highly cross-adsorbed IgG leads to low nonspecific binding.

StarBright Antibodies deliver unmatched sensitivity.
fluorescentlabelcomparison.png

Comparison of StarBright Blue 700 Secondary Antibodies (top) to IR800 labeled antibodies from LI-COR, Inc. (bottom).

The StarBright Blue 700 Secondary Antibodies have exposure times that are 30 to 100 times shorter than IR800 labeled antibodies. Instead of 5 to 10 minutes, StarBright Antibodies need only a few seconds of light exposure to detect even the least abundant protein of interest, thus reducing potential background noise.

“Because of their high sensitivity of detection and ease of use with other antibodies for multiplexing, including stain-free and/or other IR800 labeled antibodies, StarBright Secondary Antibodies allow researchers to easily identify and quantify up to three unique proteins on one blot,” said Poulomi Acharya, PhD, Bio-Rad Global Product Manager, Protein Quantitation.

One-step detection of housekeeping proteins
For scientists who want to continue using their validated housekeeping proteins for protein normalization, Bio-Rad also offers human fragment antigen-binding (hFab) primary antibodies prelabeled with rhodamine dye. The antibodies are generated using Bio-Rad’s Human Combinatorial Antibody Library (HuCAL®) technology and can be used with other primary/secondary antibodies from different species without cross-reactivity. They are versatile, detecting human, rat, and mouse housekeeping proteins (actin, tubulin, GAPDH).

These labeled primary antibodies offer convenient one-step detection of common housekeeping proteins without the need for a secondary antibody, making them more reliable and easier to use than traditional anti-housekeeping antibodies.

Both products are part of Bio-Rad’s family of instruments, reagents, and antibodies designed to obtain fluorescent western blot results reliably, reproducibly, and with high-quality data. With the recently launched ChemiDoc™ MP Imaging System, a highly sensitive and flexible fluorescent detection imaging platform, and a portfolio of unique fluorescent-labeled secondary and primary antibodies, Bio-Rad is one of the leading providers of end-to-end western blotting workflow solutions.

For researchers new to western blot imaging, Bio-Rad continues to lead the industry in customer support and online resources, including Western Blot Doctor™ and a well-stocked library of videos.

For more information about Bio-Rad’s complete line of western blotting products, please visit bio-rad.com/en-us/category/western-blotting.

For more information about StarBright Blue 700 Secondary Antibodies, please visit bio-rad.com/starbright-pr.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Poulomi Acharya
510-741-4507
Poulomi_acharya@bio-rad.com

CG Life
Ken Li
312-532-4675
kli@cglife.com